Sanofi completes acquisition of DR-0201

赛诺菲完成对DR-0201的收购

Paris, May 27, 2025.

巴黎，2025年5月27日。

Sanofi announces the completion of its

赛诺菲宣布已完成其

acquisition of

收购

DR-0201

DR-0201

, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline.

，一种由私人临床阶段生物制药公司Dren Bio, Inc.开发的靶向双特异性髓系细胞接合器。此次收购增强了赛诺菲成为免疫学领域领先公司的雄心，并拓展了该公司领先的免疫学产品管线。

DR-0201, now named SAR448501, has shown robust B-cell depletion in pre-clinical and early clinical studies. The potential first-in-class targeted bispecific myeloid cell engager targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis..

DR-0201，现名为SAR448501，在临床前和早期临床研究中显示出强大的B细胞清除效果。这种潜在的首创靶向双特异性髓系细胞接合器，靶向并结合特定的组织驻留和迁移髓系细胞，通过靶向吞噬作用诱导深度B细胞清除。

Recent pre-clinical and early clinical study data in autoimmune diseases suggest that deep B-cell depletion has the potential to reset the adaptive immune system, leading to sustained treatment-free remission in patients with refractory B-cell mediated autoimmune diseases such as lupus, where significant unmet medical needs remain..

近期在自身免疫疾病中的临床前和早期临床研究数据显示，深度B细胞耗竭有潜力重置适应性免疫系统，从而为难治性B细胞介导的自身免疫疾病（如红斑狼疮）患者带来持续的无治疗缓解，而这些疾病仍然存在显著未满足的医疗需求。

Sanofi acquired DR-0201 through the acquisition of the Dren Bio affiliate Dren 0201, Inc. for an upfront payment of $600 million and potential future payments totaling $1.3 billion upon achievements of certain development and launch milestones. Dren Bio will continue to operate independently to advance its pipeline of antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.

通过收购Dren Bio的附属公司Dren 0201, Inc.，赛诺菲以6亿美元的首付款获得了DR-0201，并在实现某些开发和上市里程碑后可能支付总计13亿美元的未来款项。Dren Bio将继续独立运营，推进其选择性清除致病细胞及其他致病因子的抗体治疗产品管线。

.

。

About Sanofi

关于赛诺菲

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions..

我们是一家创新的全球医疗保健公司，由一个宗旨驱动：我们追求科学的奇迹以改善人们的生活。我们的团队遍布全球，致力于通过努力将不可能变为可能来改变医学实践。我们为全球数百万人提供可能改变生命的治疗选择和挽救生命的疫苗保护，同时将可持续发展和社会责任置于我们目标的核心。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在欧洲证券交易所上市，代码为SAN，在纳斯达克上市，代码为SNY。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·盖恩杜尔@赛诺菲.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

evan.berland@sanofi.com

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库兹克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

thomas.larsen@sanofi.com

Alizé Kaisserian

阿利泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Felix Lauscher

费利克斯·劳舍尔

| +1 908 612 7239 |

| +1 908 612 7239 |

felix.lauscher@sanofi.com

felix.lauscher@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

娜塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

娜塔莉·法姆@赛诺菲.com

Tarik Elgoutni

塔里克·埃尔戈特尼

| +1 617 710 3587 |

| +1 617 710 3587 |

tarik.elgoutni@sanofi.com

塔里克·埃尔古蒂@赛诺菲.com

Thibaud Châtelet

蒂博·沙特莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Dren Bio

德伦生物

Jeff Macfarland

杰夫·麦克法兰

, EVP, Finance | ir@drenbio.com

执行副总裁，财务 | ir@drenbio.com

Sanofi forward-looking statements

赛诺菲前瞻性声明

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）所定义的前瞻性陈述。前瞻性陈述并非历史事实。这些陈述包括预测、估计及其基本假设，关于未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的陈述，以及关于未来业绩的陈述。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

前瞻性陈述通常可以通过“预期”、“预计”、“相信”、“打算”、“估计”、“计划”等词语及类似表述加以识别。尽管赛诺菲的管理层认为这些前瞻性陈述中反映的预期是合理的，但投资者应注意，前瞻性信息和陈述受到各种风险和不确定性的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与这些前瞻性信息和陈述所表达或暗示的内容存在重大差异。

These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and com.

这些风险和不确定性包括但不限于研发固有的不确定性、未来的临床数据和分析（包括上市后）、监管机构（如FDA或EMA）的决定，涉及是否以及何时批准任何可能为这些候选产品提交的药物、器械或生物制品申请，以及他们关于标签和其他可能影响此类候选产品可用性或商业潜力的事项的决定，候选产品即使获得批准也可能无法取得商业成功这一事实，以及未来的批准和商业化进程等。

Attachment

附件

Press Release

新闻发布

Share

分享